RayKnowChina Research Map
Shortlist0

BeijingPeking University Health Science Center

Peking University First Hospital

北京大学第一医院

Listed for 32 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Peking University First Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌19 papers led2 open trials led
  2. Stomach cancer胃癌27 papers led1 open trial led
  3. Hepatoblastoma肝母细胞瘤0 papers led
  4. Osteosarcoma骨肉瘤4 papers led1 open trial led
  5. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  6. Neuroblastoma神经母细胞瘤6 papers led
  7. Ewing sarcoma尤文肉瘤1 paper led
  8. Multiple myeloma多发性骨髓瘤17 papers led5 open trials led
  9. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症1 paper led
  10. Haemophilia A血友病 A1 paper led
  11. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征2 papers led
  12. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病1 paper led
  13. IgG4-related diseaseIgG4相关性疾病5 papers led
  14. Myasthenia gravis重症肌无力3 papers led
  15. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  16. Takayasu arteritis大动脉炎1 paper led
  17. Hepatic echinococcosis肝包虫病1 paper led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  19. Amyotrophic lateral sclerosis肌萎缩侧索硬化症2 papers led
  20. Spinal muscular atrophy脊髓性肌萎缩症1 paper led
  21. Fabry disease法布雷病8 papers led
  22. Pompe disease庞贝病1 paper led
  23. Duchenne muscular dystrophy杜氏肌营养不良11 papers led
  24. Behçet disease白塞病2 papers led
  25. Alport syndromeAlport 综合征8 papers led
  26. IgA nephropathyIgA 肾病65 papers led1 open trial led
  27. Niemann–Pick disease type C尼曼-匹克病 C 型0 papers led
  28. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  29. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  30. Hirschsprung disease先天性巨结肠1 paper led
  31. Inherited epidermolysis bullosa遗传性大疱性表皮松解症5 papers led
  32. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Retinoblastoma, Chordoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Moyamoya disease, Wilson disease, Biliary atresia, Lymphangioleiomyomatosis, Gaucher disease, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 19 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
19
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 4420232024: 8820242025: 332025

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
    Phase
    N/A
    Started
    2026-04
    Registry
    NCT07557225

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  2. Recruiting
    GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07795437

    Age 18 years to Not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  3. Recruiting
    DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06190665

    Age 18 years to 80 years (registered criteria)

    Led by Zhongda Hospital, Southeast University; 1 listed hospital as study siteBeijing, Nanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesLocal treatment (ablation, TACE, HAIC)Recurrence & prognosisHepatitis B & cirrhosis
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Rheumatology & immunologyGastroenterology / hepatology
Papers it led19
  1. Impact of altitude on hemoglobin dynamics and prognosis in patients with advanced hepatocellular carcinoma receiving antiangiogenic TKIs: A propensity score matched study.2025Cancer chemotherapy and pharmacology
  2. Baseline FIB-4 May Be a Risk Factor of Recurrence After SBRT in Patients With HBV-Related Small HCC.2025Cancer medicineFree full text
  3. Radiofrequency ablation with or without conventional transarterial chemoembolization for subcapsular versus nonsubcapsular hepatocellular carcinoma within Milan criteria: a propensity score-matched study.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  4. Feasibility of novel intraoperative navigation for anatomical liver resection using real-time virtual sonography combined with indocyanine green fluorescent imaging technology.2024Bioscience trends
  5. No Incidence of Liver Cancer Was Observed in A Retrospective Study of Patients with Aristolochic Acid Nephropathy.2024Chinese journal of integrative medicine
  6. Which is more appropriate for the evaluation of HCC, RECIST or mRECIST criteria?2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. Letter to the editor regarding "Comparing long-term survival benefits of hepatocellular carcinoma between thermal ablation monotherapy and combined therapy with transarterial chemoembolization: A propensity score matched study".2024European journal of radiology
  8. HDAC Inhibition Sensitize Hepatocellular Carcinoma to Lenvatinib via Suppressing AKT Activation.2024International journal of biological sciencesFree full text
  9. Methodological challenges in studying immune-suppressive neutrophils in HCC models.2024Journal of hepatology
  10. Letter to the editor Re "Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study".2024La Radiologia medica
  11. Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis.2024The American journal of medicine
  12. A case report of situs inversus totalis undergoing multiple interventional strategies.2023Asian journal of surgery
  13. Loadability and Releasing Profiles In Vitro and Pharmacokinetics In Vivo of Vinorelbine and Raltitrexed by CalliSpheres Beads.2023Cancer biotherapy & radiopharmaceuticals
  14. Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment.2023Frontiers in cellular and infection microbiologyFree full text
  15. Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art.2023Journal of nanobiotechnologyFree full text
  16. Long-term outcome of percutaneous radiofrequency ablation for periportal hepatocellular carcinoma: tumor recurrence or progression, survival and clinical significance.2022Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  17. Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.2022Clinics and research in hepatology and gastroenterology
  18. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  19. Genome-wide association study identifies new loci associated with risk of HBV infection and disease progression.2021BMC medical genomicsFree full text
Chinese-language papers (not in the count)2
  1. [Expression of YARS1 in hepatocellular carcinoma and its prognostic effect].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Occurrence and recurrence of hepatitis C-related hepatocellular carcinoma after direct antiviral treatment].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status5
  1. GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular CarcinomaRecruitingNCT07795437Lead sponsorN/AStart 2026-08
  2. 18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsRecruitingNCT07557225Lead sponsorN/AStart 2026-04
  3. DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCCRecruitingNCT06190665Study siteN/AStart 2023-12
  4. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  5. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT02112656Study sitePhase 3Start 2014-06

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 27 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
27
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 4420212022: 5520222023: 5520232024: 6620242025: 662025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07039474

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First HospitalBeijing

  2. Recruiting
    A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06760819

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai

  3. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  4. Recruiting
    Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07175155

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesBeijing, Hangzhou, Taizhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseSurgeryEarly detection & endoscopy
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicineMedical oncology
Papers it led27
  1. Effectiveness of the aspiration method in preventing delayed bleeding after gastric endoscopic submucosal dissection.2026Surgical endoscopyFree full text
  2. Rapid and specific immunoPET imaging of Nectin-4 in gastric cancer and non-small cell lung cancer using [64Cu]Cu-NOTA-EV-F(ab')2.2025European journal of nuclear medicine and molecular imagingFree full text
  3. Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer.2025European journal of nuclear medicine and molecular imagingFree full text
  4. Noninvasive Evaluation of Trop2 Expression Using 64Cu-NOTA-Trodelvy-F(ab')2 in Gastric and Pancreatic Cancer.2025Molecular pharmaceuticsFree full text
  5. ImmunoPET Imaging of Nectin4 Expression in Gastric and Bladder Cancer Using [64Cu]Cu-NOTA-Padcev.2025Molecular pharmaceuticsFree full text
  6. Prognostic value of neutrophil-lymphocyte ratio in gastroenteropancreatic neuroendocrine neoplasm: a systematic review and meta-analysis.2025PeerJFree full text
  7. Evaluating the efficacy and safety of neoadjuvant immunochemotherapy versus chemotherapy in locally advanced gastric cancer undergoing radical gastrectomy: a retrospective study.2025World journal of surgical oncologyFree full text
  8. Gastric metastasis from ovarian carcinoma diagnosed by EUS-FNB: A case report.2024Asian journal of surgery
  9. A solitary polyp of the stomach.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  10. Cross-talk between Helicobacter pylori and gastric cancer: a scientometric analysis.2024Frontiers in cellular and infection microbiologyFree full text
  11. Comparison of nasojejunal nutrition and intravenous nutrition supplementation in patients with upper gastrointestinal tract strictures and analysis of risk factors for malnutrition.2024MedicineFree full text
  12. Plasma metabolomics and lipidomics reveal potential novel biomarkers in early gastric cancer: An explorative study.2024The International journal of biological markers
  13. Short-and long-term outcomes of one-stage versus two-stage gastrectomy for perforated gastric cancer: a multicenter retrospective propensity score-matched study.2024World journal of surgical oncologyFree full text
  14. LncRNA CCAT2 promotes malignant progression of metastatic gastric cancer through regulating CD44 alternative splicing.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  15. Palliative Gastrectomy Improves the Survival of Patients with Metastatic Early-Onset Gastric Cancer: A Retrospective Cohort Study.2023Current oncology (Toronto, Ont.)Free full text
  16. A novel immunogenic cell death-related subtype classification and risk signature for predicting prognosis and immunotherapy efficacy in gastric cancer.2023Frontiers in immunologyFree full text
  17. The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma.2023Journal of experimental & clinical cancer research : CRFree full text
  18. A convolutional neural network-based system for detecting early gastric cancer in white-light endoscopy.2023Scandinavian journal of gastroenterology
  19. LncRNA CRART16/miR-122-5p/FOS axis promotes angiogenesis of gastric cancer by upregulating VEGFD expression.2022AgingFree full text
  20. Value of Preoperative Hematological Parameters in the Prognosis of Gastric Cancer Patients Undergoing a Total Gastrectomy.2022Current medical science
  21. CAF promotes chemoresistance through NRP2 in gastric cancer.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  22. Risk factors and characteristics of bacterial infection during first-line chemotherapy for metastatic gastric or gastroesophageal junction adenocarcinoma.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  23. Survival benefits from neoadjuvant treatment in gastric cancer: a systematic review and meta-analysis.2022Systematic reviewsFree full text
  24. Multivisceral resection for locally advanced gastric cancer: A retrospective study.2021American journal of surgery
  25. SPARC enhances 5-FU chemosensitivity in gastric cancer by modulating epithelial-mesenchymal transition and apoptosis.2021Biochemical and biophysical research communications
  26. An investigation on gastric cancer staging using CT structured report.2021European journal of radiology
  27. MiR-205-5p suppresses angiogenesis in gastric cancer by downregulating the expression of VEGFA and FGF1.2021Experimental cell research
Chinese-language papers (not in the count)1
  1. [Pathological evaluation of endoscopic submucosal dissection for early gastric cancer and precancerous lesion in 411 cases].2023Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
All its trials on ClinicalTrials.gov, any status8
  1. The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer ImmunotherapyRecruitingNCT07039474Lead sponsorStart 2026-09
  2. Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled TrialStatus unknownNCT06324825Lead sponsorN/AStart 2022-10
  3. Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese PatientsRecruitingNCT07175155Study siteN/AStart 2025-10
  4. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Study sitePhase 2Start 2025-02
  5. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  6. Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal MetastasisStatus unknownNCT04222114Study sitePhase 3Start 2020-10
  7. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric CancerTerminatedNCT02867839Study sitePhase 3Start 2017-04
  8. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

9 hospitals in Beijing for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Therapeutic effect and clinical cost of multi-disciplinary team model of hepatoblastoma in children].2020Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 112025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07774533

    Age 10 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
    Phase
    Phase 2
    Started
    2021-08
    Registry
    NCT04924075

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 6 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 222025

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsNeurology

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT06926283

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Changsha, Hangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led1
  1. Primary ewing sarcoma in the uterine cervix with multiple bone metastases.2022Archives of gynecology and obstetrics
All its trials on ClinicalTrials.gov, any status2
  1. A Study of DXC008 in Patients With Prostate Cancer and Other Solid TumorsRecruitingNCT06926283Study sitePhase 1Start 2025-05
  2. Anlotinib and Irinotecan for Ewing SarcomaStatus unknownNCT03416517Study sitePhase 1/Phase 2Start 2018-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 17 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.0%.

Papers led
17
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 7720212022: 3320222023: 0020232024: 3320242025: 442025

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
    Phase
    Phase 1
    Started
    2026-06
    Registry
    NCT07660939

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  2. Recruiting
    A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-04
    Registry
    NCT06717113

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First HospitalBeijing

  3. Recruiting
    68Ga-BCMA PET/CT in Multiple Myeloma
    Phase
    Phase 2/Phase 3
    Started
    2025-12
    Registry
    NCT07319897

    Age 18 years to 80 years (registered criteria)

    Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing, Changchun, Shijiazhuang

  4. Recruiting
    PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
    Phase
    Early phase 1
    Started
    2024-04
    Registry
    NCT06385652

    Age 18 years to 90 years (registered criteria)

    Led by Peking University First HospitalBeijing

  5. Recruiting
    A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
    Phase
    Not given
    Started
    2021-07
    Registry
    NCT05283993

    Age not stated (registered criteria)

    Led by Peking University First HospitalBeijing

  6. Recruiting
    A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07258511

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanjing, Nanning, Wenzhou, Wuhan, Xi'an

  7. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  8. Recruiting
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Hangzhou, Nanchang, Nanjing, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an

  9. Recruiting
    Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07028970

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou

  10. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  11. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskKidney & bone complicationsBispecific & antibody drugs
Departments in papersRadiology / nuclear medicinePathology / laboratory medicine
Papers it led17
  1. Metabolomics and machine learning approaches for diagnostic biomarkers screening in systemic light chain amyloidosis.2025Annals of hematologyFree full text
  2. CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies.2025European journal of nuclear medicine and molecular imaging
  3. B-cell maturation antigen targeted PET/CT imaging in multiple myeloma: a first-in-human study.2025Journal of hematology & oncologyFree full text
  4. Development and Preclinical Validation of a Novel 89Zr-Labeled BCMA-Targeting Antibody for ImmunoPET Imaging: Application in Multiple Myeloma Models and First-In-Nonhuman-Primates.2025Journal of medicinal chemistry
  5. Pharmacokinetic Positron Emission Tomography Imaging of an Optimized CD38-Targeted 68Ga-Labeled Peptide in Multiple Myeloma: A Pilot Study.2024Bioconjugate chemistry
  6. 5-Hydroxymethylcytosine Profiles of cfDNA in Urine as Diagnostic, Differential Diagnosis and Prognostic Markers for Multiple Myeloma.2024Cancer medicineFree full text
  7. Development of a Novel Peptide-Based PET Tracer [68Ga]Ga-DOTA-BP1 for BCMA Detection in Multiple Myeloma.2024Journal of medicinal chemistry
  8. Identification of CD8+ T-cell epitope from multiple myeloma-specific antigen AKAP4.2022Frontiers in immunologyFree full text
  9. Prognostic Factors of AL-PCMM and AL-MM: A Single-Center Retrospective Study.2022International journal of medical sciencesFree full text
  10. Clinical Characteristics and Prognosis of Multiple Myeloma With Myelomatous Pleural Effusion: A Retrospective Single-Center Study.2022Technology in cancer research & treatmentFree full text
  11. Myeloma cast nephropathy with diffuse amyloid casts without systemic amyloidosis: two cases report.2021BMC nephrologyFree full text
  12. Crystalline appearance in light chain cast nephropathy is associated with higher early mortality in patients with newly diagnosed multiple myeloma.2021International immunopharmacology
  13. Coexistent light chain deposition disease, light chain cast nephropathy, and vascular light chain amyloidosis in a patient with IgD lambda multiple myeloma.2021International urology and nephrology
  14. Contradictory Phenomenon Between Serum Separator Tube and Plasma Tube: A Case Report.2021Laboratory medicine
  15. Crystals in myeloma cast nephropathy.2021QJM : monthly journal of the Association of Physicians
  16. Crystalline light chain cast nephropathy in multiple myeloma.2021The Korean journal of internal medicineFree full text
  17. C3 glomerulonephritis along with light chain proximal tubulopathy without crystal deposits in multiple myeloma: a case report.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)2
  1. [Screening and Preliminary Validation of Multiple Myeloma Specific Proteins].2025Zhongguo shi yan xue ye xue za zhi
  2. [The indication of renal biopsy and novel understanding of pathological manifestations in multiple myeloma-related renal].2024Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status22
  1. GPRC5D Targeted PET/CT Imaging in Plasma Cell DisordersRecruitingNCT07660939Lead sponsorPhase 1Start 2026-06
  2. A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple MyelomaRecruitingNCT06717113Lead sponsorEarly phase 1Start 2025-04
  3. 68Ga-BCMA PET/CT in Multiple MyelomaRecruitingNCT07319897Lead sponsorPhase 2/Phase 3Start 2025-12
  4. PET Imaging Study of 68Ga-NB381 in Multiple MyelomaRecruitingNCT06385652Lead sponsorEarly phase 1Start 2024-04
  5. A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFHRecruitingNCT05283993Lead sponsorStart 2021-07
  6. A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMMStatus unknownNCT06203145Lead sponsorN/AStart 2024-01
  7. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07518186Study sitePhase 3Start 2026-05
  8. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT07258511Study sitePhase 3Start 2026-02
  9. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  10. Long-term Follow-up Registry Study of Equecabtagene Autoleucel InjectionRecruitingNCT07028970Study siteStart 2024-12
  11. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  12. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  13. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  14. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  15. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Study sitePhase 3Start 2022-10
  16. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  17. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05083169Study sitePhase 3Start 2021-10
  18. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05
  19. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Study sitePhase 1/Phase 2Start 2020-04
  20. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT04557098Study sitePhase 2Start 2020-09
  21. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  22. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 1 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

11 hospitals in Beijing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesTreatment regimensLymphoma & cancer-related HLH

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Peripheral Blood Lymphocyte Subsets in Factor VIII Inhibitor-Positive Patients with Severe Hemophilia A: A Case-Control Study.2024Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
Chinese-language papers (not in the count)1
  1. [Pharmacokinetic Study of Coagulation Factor Ⅷ in Adults with Severe Hemophilia A].2024Zhongguo shi yan xue ye xue za zhi

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 2 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 7.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Beijing for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 1 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBiologic drugsRelapse preventionAcute attack treatment
Departments in papersPediatrics
Papers it led1
  1. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease.2023Multiple sclerosis and related disorders
Chinese-language papers (not in the count)1
  1. [Clinical follow-up study of myelin oligodendrocyte glycoprotein antibody-associated disease in children].2021Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 5 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 2.0%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 0020242025: 222025

11 hospitals in Beijing for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesKidney, retroperitoneum & vesselsPancreas & bile ductsDiagnosis & look-alikes
Departments in papersNeurologyNephrologyRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 3 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBiologic & complement drugsStandard immunotherapyAntibodies & diagnosis
Departments in papersNeurology
Papers it led3
  1. COVID-19 in patients with myasthenia gravis: a single-center retrospective study in China.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  2. Long-Term Efficacy and Safety of Low-Dose Rituximab in Patients with Refractory Myasthenia Gravis.2023European neurology
  3. Myasthenia gravis associated with renal cell carcinoma: a paraneoplastic syndrome or just a coincidence.2021BMC neurologyFree full text
Chinese-language papers (not in the count)1
  1. [Efficacy and safety of rituximab in the treatment of pediatric myasthenia gravis].2024Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Study sitePhase 2/Phase 3Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. A 16-year-old girl with sudden heart failure and nephrotic syndrome associated with Takayasu's arteritis.2022Clinical research in cardiology : official journal of the German Cardiac Society
Earlier papers (2016–2020)1
  1. Unusual Collateral Vascular Development in a Patient with Takayasu Arteritis.2018Journal of vascular and interventional radiology : JVIR

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Beijing for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 3320232024: 0020242025: 112025

27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 2 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

19 hospitals in Beijing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 1 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

8 hospitals in Beijing for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Registry
    NCT07554924

    Age Not stated to 180 days (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Shanghai

  2. Recruiting
    Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06971094

    Age 2 years to 12 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Shenzhen, Suzhou, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results.2024Advances in therapy
Chinese-language papers (not in the count)1
  1. [Analysis of 4 children with DYNC1H1 gene related spinal muscular atrophy with lower extremity predominant 1].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status7
  1. A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type IRecruitingNCT07554924Study sitePhase 1/Phase 2Start 2026-07
  2. Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase IIIRecruitingNCT06971094Study sitePhase 3Start 2025-05
  3. Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)CompletedNCT05089656Study sitePhase 3Start 2022-02
  4. A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)CompletedNCT04729907Study sitePhase 3Start 2021-04
  5. Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyCompletedNCT04089566Study sitePhase 3Start 2020-03
  6. A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) ParticipantsCompletedNCT02908685Study sitePhase 2Start 2016-10
  7. Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular AtrophyCompletedNCT02913482Study sitePhase 2Start 2016-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 8 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 11.0%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 442025

11 hospitals in Beijing for Fabry disease85 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyOphthalmology / neuro-ophthalmology
Papers it led8
  1. The vestibular and oculomotor dysfunction in Fabry disease: a cohort study in China.2025Annals of medicine
  2. Elevated circulating cell-free mitochondrial DNA in fabry disease: insights into inflammatory activation.2025Frontiers in immunology
  3. Corneal neuro-immune crosstalk in Fabry disease: An in vivo confocal microscopic study.2025Journal of neuroimmunology
  4. Deep learning assisted retinal microvasculature assessment and cerebral small vessel disease in Fabry disease.2025Orphanet journal of rare diseases
  5. Inflammatory cytokine expression in Fabry disease: impact of disease phenotype and alterations under enzyme replacement therapy.2024Frontiers in immunology
  6. Evaluation of global and regional myocardial work by echocardiography in patients with Fabry disease.2024Orphanet journal of rare diseases
  7. Investigation of ocular involvement in patients with Fabry disease.2023Annals of medicine
  8. Brain MRI correlations with disease burden and biomarkers in Fabry disease.2023Journal of neurology
Chinese-language papers (not in the count)1
  1. [Hypertrophic obstructive cardiomyopathy associated with Fabry disease: a case report].2025Zhonghua nei ke za zhi
Earlier papers (2016–2020)1
  1. Plasma lipidomic analysis of sphingolipids in patients with large artery atherosclerosis cerebrovascular disease and cerebral small vessel disease.2020Bioscience reports
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseRecruitingNCT07187440Study siteStart 2025-11
  2. Study of the Safety and Biologic Activity of AL01211 in Treatment Naive Males With Classic Fabry DiseaseStatus unknownNCT06114329Study sitePhase 2Start 2023-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led 1 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

6 hospitals in Beijing for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 11 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 5.2%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 4420232024: 5520242025: 222025

11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyPediatrics
Papers it led11
  1. Interleukin-17B is a new biomarker of human muscle regeneration in dystrophinopathies.2025Brain : a journal of neurology
  2. RNA sequencing facilitates the identification of genetic causes of Duchenne muscular dystrophy and proposes a stepwise DMD diagnostic procedure.2025Gene
  3. Single-Nucleus RNA Sequencing Unravels Early Mechanisms of Human Becker Muscular Dystrophy.2024Annals of neurology
  4. Prevalence of Adeno-Associated Virus-9-Neutralizing Antibody in Chinese Patients with Duchenne Muscular Dystrophy.2024Human gene therapy
  5. A novel biomarker of fibrofatty replacement in dystrophinopathies identified by integrating transcriptome, magnetic resonance imaging, and pathology data.2024Journal of cachexia, sarcopenia and muscle
  6. A new pseudoexon activation due to ultrarare branch point formation in Duchenne muscular dystrophy.2024Neuromuscular disorders : NMD
  7. Clinical and genetic interpretation of uncertain DMD missense variants: evidence from mRNA and protein studies.2024Orphanet journal of rare diseases
  8. Cryptic exon activation caused by a novel deep-intronic splice-altering variant in Becker muscular dystrophy.2023Journal of clinical laboratory analysis
  9. Clinical, muscle imaging, and genetic characteristics of dystrophinopathies with deep-intronic DMD variants.2023Journal of neurology
  10. Clinical, pathological, and genetic characterization in a large Chinese cohort with female dystrophinopathy.2023Neuromuscular disorders : NMD
  11. Characteristics and feasibility of ambulatory respiratory assessment of paediatric neuromuscular disease: an observational retrospective study.2023The International journal of neuroscience
Chinese-language papers (not in the count)2
  1. [Screening for Duchenne muscular dystrophy in newborns in the Ningxia region].2024Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  2. [Clinical and genetic characteristics of 9 rare cases with coexistence of dual genetic diagnoses].2023Zhonghua er ke za zhi = Chinese journal of pediatrics
Earlier papers (2016–2020)4
  1. Long-read whole-genome sequencing for the genetic diagnosis of dystrophinopathies.2020Annals of clinical and translational neurology
  2. Splicing Characteristics of Dystrophin Pseudoexons and Identification of a Novel Pathogenic Intronic Variant in the DMD Gene.2020Genes
  3. T2 Mapping and Fat Quantification of Thigh Muscles in Children with Duchenne Muscular Dystrophy.2019Current medical science
  4. [Magnetic resonance imaging of dystrophinopathy that mimics adductor enthesopathy].2016Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
All its trials on ClinicalTrials.gov, any status1
  1. A Natural History Study In Chinese Male Patients With Duchenne Muscular DystrophyCompletedNCT03760029Study siteN/AStart 2019-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    Phase
    Phase 3
    Started
    2023-11
    Registry
    NCT06145893

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Guangzhou, Guilin, Hangzhou, Linyi, Nanchang, Shanghai, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Xiamen, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led2
  1. Surgical intervention and management of Behcet disease with perianal abscess: A case report.2024Asian journal of surgery
  2. Behcet's-like disease induced by secukinumab in a patient with psoriasis: a case report and literature review.2024The Journal of dermatological treatment
Earlier papers (2016–2020)1
  1. [Panuveitis with oral and genital ulcer misdiagnosed as Behcet's disease: two cases report and literature review].2016Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's DiseaseRecruitingNCT06145893Study sitePhase 3Start 2023-11
  2. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 8 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 13.8%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 3320232024: 1120242025: 112025

7 hospitals in Beijing for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsOphthalmology / neuro-ophthalmology
Papers it led8
  1. A retrospective study of kidney disease in Alport syndrome during and after pregnancy.2025Journal of nephrology
  2. Characterization of Ocular Morphology in Col4a3-/- Mice as a Murine Model for Alport Syndrome.2024Translational vision science & technology
  3. Primary membranous nephropathy in two siblings with one combined with anti-glomerular basement membrane disease: a case report.2023BMC nephrology
  4. Genetic Variants of the COL4A3 , COL4A4 , and COL4A5 Genes Contribute to Thinned Glomerular Basement Membrane Lesions in Sporadic IgA Nephropathy Patients.2023Journal of the American Society of Nephrology : JASN
  5. Combined Alport syndrome, Klinefelter syndrome and Fanconi syndrome in a Chinese boy.2023Nephrology (Carlton, Vic.)
  6. A woman with Alport syndrome in compound-heterozygous state in pregnancy: lessons for the clinical nephrologist.2022Journal of nephrology
  7. Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.2021Pediatric nephrology (Berlin, Germany)
  8. mRNA analysis identifies deep intronic variants causing Alport syndrome and overcomes the problem of negative results of exome sequencing.2021Scientific reports
Earlier papers (2016–2020)12
  1. Reassessing the pathogenicity of c.2858G>T(p.(G953V)) in COL4A5 Gene: report of 19 Chinese families.2020European journal of human genetics : EJHG
  2. [Clinical phenotype of Alport syndrome in monozygotic twins].2020Zhonghua er ke za zhi = Chinese journal of pediatrics
  3. Dysregulated Expression of microRNA-21 and Disease-Related Genes in Human Patients and in a Mouse Model of Alport Syndrome.2019Human gene therapy
  4. Effect of heterozygous pathogenic COL4A3 or COL4A4 variants on patients with X-linked Alport syndrome.2019Molecular genetics & genomic medicine
  5. X-linked Alport syndrome: pathogenic variant features and further auditory genotype-phenotype correlations in males.2018Orphanet journal of rare diseases
  6. Urinary epidermal growth factor as a prognostic marker for the progression of Alport syndrome in children.2018Pediatric nephrology (Berlin, Germany)
  7. Renal, auricular, and ocular outcomes of Alport syndrome and their current management.2018Pediatric nephrology (Berlin, Germany)
  8. [Detection of large deletions in X linked Alport syndrome using competitive multiplex fluorescence polymerase chain reaction].2017Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  9. Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome.2017Kidney international
  10. Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.2016Pediatric nephrology (Berlin, Germany)
  11. [Analysis of diagnosis and treatment of Alport syndrome].2016Zhonghua er ke za zhi = Chinese journal of pediatrics
  12. [Clinical and genetic features of X-linked Alport syndrome in men positive for the collagen Ⅳ α5 chain in epidermal basement membrane].2016Zhonghua er ke za zhi = Chinese journal of pediatrics
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Learn About How Well BAY 3401016 Works in Adults With Alport SyndromeActive, not recruitingNCT07211685Study sitePhase 2Start 2025-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 65 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 8.8%.

Papers led
65
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
8
led by another institution
Papers led per year
2021: 141420212022: 101020222023: 121220232024: 171720242025: 992025

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic Strategies
    Phase
    N/A
    Started
    2026-08
    Registry
    NCT07822100

    Age 18 years to 75 years (registered criteria)

    Led by Peking University First HospitalBeijing

  2. Recruiting
    A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
    Phase
    Phase 1/Phase 2
    Started
    2026-02
    Registry
    NCT07375758

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  3. Recruiting
    Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07390123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changchun, Changsha, Huangshan City, Linyi, Shanghai, Wuhu, Xi'an, Zhanjiang

  4. Recruiting
    A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07582133

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  5. Recruiting
    Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07614477

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin

  6. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

  7. Recruiting
    A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-06
    Registry
    NCT07014826

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  8. Recruiting
    A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07616700

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  9. Recruiting
    Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy
    Phase
    Phase 2
    Started
    2023-05
    Registry
    NCT05775042

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatricsNephrology
Papers it led65
  1. The Association of Proteinuria Target Achievement Timing and Stability with Adverse Kidney Outcomes among Patients with IgA Nephropathy: A Cohort Study.2026American journal of nephrology
  2. CFHR3*B Haplotype, Complement Activation, and Risk of IgA Nephropathy.2026Journal of the American Society of Nephrology : JASN
  3. Genetic Determinants of Steroid Responsiveness in IgA Nephropathy.2026Journal of the American Society of Nephrology : JASNRCT
  4. New thoughts on the intestinal microbiome-B cell-IgA axis and therapies in IgA nephropathy.2025Autoimmunity reviews
  5. Expanding the spectrum of genetic causes of DNA-specific exonuclease TREX1 variants in thrombotic microangiopathy.2025Kidney international
  6. Red blood cell casts on kidney biopsy and progression of IgA nephropathy.2025Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  7. Long-term outcomes of IgA nephropathy in China.2025Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  8. Efficacy and Safety of Telitacicept in IgA Nephropathy: A Retrospective, Multicenter Study.2025Nephron
  9. Efficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis nephropathy in adolescents: a case series.2025Pediatric nephrology (Berlin, Germany)
  10. Causal relationships between gut microbiota and IgA nephropathy: evidence from Mendelian randomization and microbiome validation.2025Renal failure
  11. Origin of poorly galactosylated IgA1 other than mucosa: a viewpoint from a report on patient with IgA vasculitis.2025Renal failure
  12. The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk.2025Theranostics
  13. Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study.2024American journal of kidney diseases : the official journal of the National Kidney Foundation
  14. Clinical Implications of C2 Lesion in IgA Nephropathy: A Cohort Study.2024American journal of nephrology
  15. Sunitinib-induced endocapillary proliferative glomerulonephritis with IgA2 deposit in addition to thrombotic microangiopathy: a case report.2024BMC nephrology
  16. Heterozygous mutations in factor H aggravate pathological damage in a stable IgA deposition model induced by Lactobacillus casei cell wall extract.2024Frontiers in immunology
  17. Unveiling biomarkers and therapeutic targets in IgA nephropathy through large-scale blood transcriptome analysis.2024International immunopharmacology
  18. A cluster of type I interferon-regulated genes associates with disease activity and prognosis in patients with IgA nephropathy.2024International immunopharmacology
  19. Circulating Proteins and IgA Nephropathy: A Multiancestry Proteome-Wide Mendelian Randomization Study.2024Journal of the American Society of Nephrology : JASN
  20. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.2024Kidney internationalRCT
  21. Efficacy and Safety of Nefecon in Patients with IgA Nephropathy from Mainland China: 2-Year NefIgArd Trial Results.2024Kidney360RCT
  22. Targeted release of budesonide in primary IgA nephropathy.2024Lancet (London, England)
  23. Low dose glucocorticoids, mycophenolate mofetil and hydroxychloroquine in IgA nephropathy, an update of current clinical trials.2024Nephrology (Carlton, Vic.)
  24. Current understanding and new insights in the treatment of IgA nephropathy.2024Nephrology (Carlton, Vic.)
  25. Association between urinary C4d levels and disease progression in IgA nephropathy.2024Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  26. Genetics of IgA nephrology: risks, mechanisms, and therapeutic targets.2024Pediatric nephrology (Berlin, Germany)
  27. Are children with IgA nephropathy different from adult patients?2024Pediatric nephrology (Berlin, Germany)
  28. Prognosis of IgA nephropathy patient with proteinuria remission by supportive therapy: cohort from screening failed Chinese patients in TESTING study.2024Renal failure
  29. The Genetics of IgA Nephropathy: Implications for Future Therapies.2024Seminars in nephrology
  30. Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy: a two-year follow-up study.2023BMC nephrology
  31. Mesangial C3 Deposition, Complement-Associated Variant, and Disease Progression in IgA Nephropathy.2023Clinical journal of the American Society of Nephrology : CJASN
  32. Machine learning in predicting T-score in the Oxford classification system of IgA nephropathy.2023Frontiers in immunology
  33. Global trends and hotspots in IgA nephropathy: a bibliometric analysis and knowledge map visualization from 2012 to 2023.2023International urology and nephrology
  34. The spectrum and changes of biopsy-proven kidney diseases in Chinese children.2023Journal of nephrology
  35. Genetic Variants of the COL4A3 , COL4A4 , and COL4A5 Genes Contribute to Thinned Glomerular Basement Membrane Lesions in Sporadic IgA Nephropathy Patients.2023Journal of the American Society of Nephrology : JASN
  36. MTMR3 risk alleles enhance Toll Like Receptor 9-induced IgA immunity in IgA nephropathy.2023Kidney international
  37. Glucocorticoids for IgA nephropathy-pro.2023Kidney international
  38. Intensive blood pressure control and the progression of IgA nephropathy: a cohort study using marginal structural models.2023Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  39. Corticosteroids in the treatment of IgA nephropathy: lessons from the TESTING trial.2023Pediatric nephrology (Berlin, Germany)
  40. Diagnosis and treatment of IgA nephropathy and IgA vasculitis nephritis in Chinese children.2023Pediatric nephrology (Berlin, Germany)
  41. Urinary epidermal growth factor predicts complete remission of proteinuria in Chinese children with IgA nephropathy.2023Pediatric research
  42. The clinical and pathological characteristics of IgA nephropathy patients in Tibet.2022BMC nephrology
  43. Concurrent IgA Nephropathy and Membranous Nephropathy, Is It an Overlap Syndrome?2022Frontiers in immunology
  44. Complement factor H variants are associated with microangiopathy lesions in IgA nephropathy.2022International immunopharmacology
  45. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.2022JAMARCT
  46. The effect of immunosuppressive therapy in patients with fibrinoid necrosis lesions in a large cohort of patients with IgA nephropathy.2022Journal of nephrology
  47. Long-term safety and efficacy of hydroxychloroquine in patients with IgA nephropathy: a single-center experience.2022Journal of nephrology
  48. The efficacy and safety of hydroxychloroquine in pregnant patients with IgA nephropathy: A retrospective cohort study.2022Nephrology (Carlton, Vic.)
  49. The level of urinary C4d is associated with disease progression in IgA nephropathy with glomerular crescentic lesions: a cohort study.2022Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  50. Clinical and Pathological Features of Renal Presentations in Polycythemia Vera.2022The American journal of the medical sciences
  51. Sustained release of Lactobacillus casei cell wall extract can induce a continuous and stable IgA deposition model.2022The Journal of pathology
  52. Collectin11 and Complement Activation in IgA Nephropathy.2021Clinical journal of the American Society of Nephrology : CJASN
  53. Poly-IgA Complexes and Disease Severity in IgA Nephropathy.2021Clinical journal of the American Society of Nephrology : CJASN
  54. Exome Chip Analyses and Genetic Risk for IgA Nephropathy among Han Chinese.2021Clinical journal of the American Society of Nephrology : CJASN
  55. Potential Roles of Oral Microbiota in the Pathogenesis of Immunoglobin A Nephropathy.2021Frontiers in cellular and infection microbiology
  56. Complement Activation Is Associated With Crescents in IgA Nephropathy.2021Frontiers in immunology
  57. A Functional Variant rs3093023 in CCR6 Is Associated With IgA Nephropathy by Regulating Th17 Cells in a North Han Chinese Population.2021Frontiers in immunology
  58. Immune characteristics of renal allograft donors with mesangial IgA deposition.2021International immunopharmacology
  59. Urinary sediments could differentiate endocapillary proliferative lupus nephritis and endocapillary proliferative IgA nephropathy.2021International immunopharmacology
  60. Interaction between GALNT12 and C1GALT1 Associates with Galactose-Deficient IgA1 and IgA Nephropathy.2021Journal of the American Society of Nephrology : JASN
  61. Shared genetic study gives insights into the shared and distinct pathogenic immunity components of IgA nephropathy and SLE.2021Molecular genetics and genomics : MGG
  62. O-glycoforms of polymeric immunoglobulin A1 in the plasma of patients with IgA nephropathy are associated with pathological phenotypes.2021Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  63. Mass spectrometry-based screening identifies circulating immunoglobulinA-α1-microglobulin complex as potential biomarker in immunoglobulin A nephropathy.2021Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  64. Associations of ABO blood type and galactose-deficient immunoglobulin A1 with adverse outcomes in patients with IgA nephropathy.2021Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  65. Is IgA nephropathy the same disease in different parts of the world?2021Seminars in immunopathology
Chinese-language papers (not in the count)5
  1. [Interpretation of the clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis in China (2025)].2025Zhonghua nei ke za zhi
  2. [The standardization process and clinical challenges in the diagnosis and treatment of IgA nephropathy in China:commentary on the clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis i2025Zhonghua nei ke za zhi
  3. [Immunomodulatory effects and research progresses of budesonide enteric-coated capsules in IgA nephropathy].2025Zhonghua nei ke za zhi
  4. [IgA nephropathy: current treatment status, prospects, opportunities, and challenges].2024Zhonghua nei ke za zhi
  5. [Clinical and genetic analysis of a child with co-morbid progressive IgA nephropathy and COQ8B-associated glomerulopathy].2024Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Earlier papers (2016–2020)29
  1. Persistent Hematuria and Kidney Disease Progression in IgA Nephropathy: A Cohort Study.2020American journal of kidney diseases : the official journal of the National Kidney Foundation
  2. Effect of hydroxychloroquine in patients with IgA nephropathy with insufficient responses to immunosuppressive therapy: a retrospective case-control study.2020BMC nephrology
  3. Neutrophil-to-lymphocyte ratio as an independent inflammatory indicator of poor prognosis in IgA nephropathy.2020International immunopharmacology
  4. MicroRNA-21-5p participates in IgA nephropathy by driving T helper cell polarization.2020Journal of nephrology
  5. Variation in complement factor H affects complement activation in immunoglobulin A vasculitis with nephritis.2020Nephrology (Carlton, Vic.)
  6. Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis.2020Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  7. Helicobacter pylori infection is associated with elevated galactose-deficient IgA1 in IgA nephropathy.2020Renal failure
  8. [Efficacy and safety of steroid combined with immunosuppressants in the treatment of primary IgA nephropathy in children: a Meta analysis].2020Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  9. Microangiopathic Lesions in IgA Nephropathy: A Cohort Study.2019American journal of kidney diseases : the official journal of the National Kidney Foundation
  10. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.2019American journal of kidney diseases : the official journal of the National Kidney FoundationRCT
  11. Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study.2019BMC nephrology
  12. [Trans-ethnic analysis of susceptibility variants in IgA nephropathy].2019Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  13. Plasma Galactose-Deficient IgA1 and C3 and CKD Progression in IgA Nephropathy.2019Clinical journal of the American Society of Nephrology : CJASN
  14. Autophagy in Immune-Related Renal Disease.2019Journal of immunology research
  15. Urine afamin and afamin-creatinine ratio as biomarkers for kidney injury.2018Biomarkers in medicine
  16. Insights into the Role of Mucosal Immunity in IgA Nephropathy.2018Clinical journal of the American Society of Nephrology : CJASN
  17. Value of the Oxford classification of IgA nephropathy in children with Henoch-Schönlein purpura nephritis.2018Journal of nephrology
  18. Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy.2018Kidney international
  19. Update on treatment of immunoglobulin A nephropathy.2018Nephrology (Carlton, Vic.)
  20. Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy.2018Renal failure
  21. Coding and Noncoding Variants in CFH Act Synergistically for Complement Activation in Immunoglobulin A Nephropathy.2018The American journal of the medical sciences
  22. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.2017BMC nephrology
  23. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.2017JAMARCT
  24. Mannose-Binding Lectin Levels Could Predict Prognosis in IgA Nephropathy.2017Journal of the American Society of Nephrology : JASN
  25. Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy.2017PloS one
  26. Plasma Exchange as an Adjunctive Therapy for Crescentic IgA Nephropathy.2016American journal of nephrology
  27. Measures of Urinary Protein and Albumin in the Prediction of Progression of IgA Nephropathy.2016Clinical journal of the American Society of Nephrology : CJASN
  28. Elevated Plasma α-Defensins (HNP1-3) Levels Correlated with IgA1 Glycosylation and Susceptibility to IgA Nephropathy.2016Disease markers
  29. Rare Variants in the Complement Factor H-Related Protein 5 Gene Contribute to Genetic Susceptibility to IgA Nephropathy.2016Journal of the American Society of Nephrology : JASN
All its trials on ClinicalTrials.gov, any status30
  1. A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA NephropathyCompletedNCT02942381Lead sponsorPhase 2Start 2016-09
  2. Trial of Plasma Exchange for Severe Crescentic IgA NephropathyTerminatedNCT02647255Lead sponsorPhase 2/Phase 3Start 2016-03
  3. Registry of IgA Nephropathy in Chinese ChildrenStatus unknownNCT03015974Lead sponsorStart 2016-01
  4. To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic IgA-targeted Therapeutic StrategiesRecruitingNCT07822100Lead (inferred)N/AStart 2026-08
  5. Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled StudyCompletedNCT02351752Lead (inferred)Phase 4Start 2015-01
  6. Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANRecruitingNCT07390123Study sitePhase 3Start 2026-04
  7. A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA NephropathyRecruitingNCT07582133Study sitePhase 2Start 2026-07
  8. A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.RecruitingNCT07375758Study sitePhase 1/Phase 2Start 2026-02
  9. Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular DiseasesRecruitingNCT07614477Study sitePhase 2Start 2026-05
  10. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  11. A Trial of HRS-5965 Capsule in Primary IgA NephropathyRecruitingNCT07014826Study sitePhase 3Start 2025-06
  12. A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA NephropathyRecruitingNCT07616700Study sitePhase 2Start 2025-08
  13. Clinical Study of CM338 in the Treatment of Immunoglobulin A NephropathyRecruitingNCT05775042Study sitePhase 2Start 2023-05
  14. Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A)Not yet recruitingNCT07730632Study sitePhase 2Start 2026-08
  15. IBI3034 Study in Healthy Adults and Patients With Primary IgA NephropathyNot yet recruitingNCT07886476Study sitePhase 1Start 2026-10
  16. Efficacy and Safety Study of HS-10542 for IgA NephropathyNot yet recruitingNCT07474636Study sitePhase 2Start 2026-03
  17. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06
  18. Study of CM313 in Subject With IgA NephropathyNot yet recruitingNCT06830395Study sitePhase 2Start 2025-09
  19. A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyActive, not recruitingNCT07305974Study sitePhase 2Start 2025-09
  20. A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune DiseasesNot yet recruitingNCT06774664Study sitePhase 1/Phase 2Start 2025-01
  21. Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)Not yet recruitingNCT06687174Study sitePhase 2Start 2024-12
  22. Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANCompletedNCT06670352Study sitePhase 2Start 2024-10
  23. A Phase IIa Study in Primary IgA Nephropathy PatientsCompletedNCT07634744Study sitePhase 2Start 2024-12
  24. A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA NephropathyStatus unknownNCT06635772Study sitePhase 2Start 2024-11
  25. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of ProgressionActive, not recruitingNCT05797610Study sitePhase 3Start 2023-08
  26. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  27. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  28. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  29. A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) NephropathyCompletedNCT04291781Study sitePhase 2Start 2020-04
  30. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led no English-language PubMed papers on Niemann–Pick disease type C in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Beijing for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy of Miglustat in Chinese NPC PatientsCompletedNCT03910621Study sitePhase 4Start 2020-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

16 hospitals in Beijing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

10 hospitals in Beijing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 1 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Beijing for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. Electro-clinical features of Mowat-Wilson syndrome: A retrospective study of 31 children in mainland China.2026Epileptic disorders : international epilepsy journal with videotape
Chinese-language papers (not in the count)1
  1. [Clinical features of epilepsy in 5 children with Mowat-Wilson syndrome].2022Zhonghua er ke za zhi = Chinese journal of pediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 5 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 8.9%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 1120242025: 002025

4 hospitals in Beijing for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

7 hospitals in Beijing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019.2024Hepatology international
Earlier papers (2016–2020)1
  1. [Concurrent APC and MLH1mutations identified in a family affected with familial adenomatous polyposis].2018Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

北京大学第一医院

Peking University First Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Peking University First Hospital-Miyun Hospital; Beida Hospital

Suggest a correctionDownload the data